In a Phase III OAK study comparing atezolizumab (anti-PD-L1 antibody) with docetaxel (chemotherapeutic) in late-stage patients with previously treated NSCLC, subgroup analysis showed that, compared with docetaxel, atezolizumab also improved overall survival (OS) in asymptomatic patients with stable brain metastases who had previously received local treatment [7]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.